CATO Research Announces Merger With SMS-Oncology
OCTOBER 28, 2019 Combination Broadens Company’s Global Solutions Supporting Drug Development DURHAM, N.C. – Cato Research, LLC (CATO) announced today that it has merged with Specialized Medical Services-oncology BV (SMS-oncology) to bolster its portfolio of global solutions dedicated to supporting life science organizations with advancing drug development. The combined company will transition to the new name, CATO SMS, in […]
Pharm-Olam names new CEO, Dr. Robert Davie
Pharm-Olam appoints former Covance executive Robert Davie, Ph.D., as CEO to succeed David Grange and continue Pharm-Olam’s growth and support of clinical drug development as a premier CRO. OCTOBER 9, 2019 Pharm-Olam, a global midsized CRO, today announced that the company’s board of directors has elected Robert Davie, Ph.D., as its new chief executive officer. Pharm-Olam […]
Importance of Natural History Studies to Rare Disease Drug Development
Pharm-Olam’s Dr. Jovana Vlajkovic-Josic, discusses why natural history studies are ‘essential’ to rare / orphan disease clinical development strategies with Outsourcing-Pharma. AUGUST 12, 2019 When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this article, Pharm-Olam’s Dr. Jovana Vlajkovic-Josic was interviewed by Melissa Fassbender […]
Pharm-Olam Webinar Helps Sponsors Manage Rescue Study Transitions
Pharm-Olam will be sharing key strategies for pharmaceutical companies needing to transition studies to a different CRO in a free webinar on June 18th. JULY 29, 2019 Houston, June 10th, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines and rare diseases, will be sharing key strategies for […]
Cato Research Appoints Life Sciences Leader And Innovator To Executive Chairman
APRIL 19, 2019 Dr. Mark Goldberg Joins Board to Support Company’s Growth and ExpansionDURHAM, NC – April 3, 2019 – Cato Research, LLC (CATO), a global provider ofregulatory and clinical research services, announced today that its board of directorshas appointed Mark Goldberg, M.D. to executive chairman, effective immediately. Dr.Goldberg brings to CATO more than 25 […]
Pharm-Olam Wins 2019 CRO Leadership Awards
Pharm-Olam LLC, is the winner of 3 Life Science Leader’s CRO leadership awards in 2019: Compatibility, Quality, and Reliability. APRIL 3, 2019 Houston, April 3rd, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science […]
Celebrating 25-Year Anniversary and Enhanced Rare Disease Services
We are celebrating 25 years of excellence and we have enhanced our rare disease services MARCH 6, 2019 Houston, March 6, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines, and rare diseases, is marking its 25th anniversary with several announcements. These include an update to its rare […]
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study FEBRUARY 5, 2019 Houston, Feb. 5, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the […]